Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use.
Loading...
Embargo End Date
ICR Authors
Authors
Ferris, RL
Licitra, L
Fayette, J
Even, C
Blumenschein, G
Harrington, KJ
Guigay, J
Vokes, EE
Saba, NF
Haddad, R
Ramkumar, S
Russell, J
Brossart, P
Tahara, M
Colevas, AD
Concha-Benavente, F
Lynch, M
Li, L
Gillison, ML
Licitra, L
Fayette, J
Even, C
Blumenschein, G
Harrington, KJ
Guigay, J
Vokes, EE
Saba, NF
Haddad, R
Ramkumar, S
Russell, J
Brossart, P
Tahara, M
Colevas, AD
Concha-Benavente, F
Lynch, M
Li, L
Gillison, ML
Document Type
Journal Article
Date
2019-09-01
Date Accepted
2019-06-21
Abstract
PURPOSE: Cetuximab, which modulates immune responses, may affect the efficacy of subsequent immunotherapy. Here, we assessed outcomes with nivolumab, by prior cetuximab exposure, in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) who had experienced progression within 6 months of platinum-containing chemotherapy. PATIENTS AND METHODS: In the randomized, open-label, phase III CheckMate 141 trial, patients were randomized 2:1 to nivolumab 3 mg/kg every 2 weeks or investigator's choice (IC) of single-agent chemotherapy, with stratification by prior cetuximab exposure. The primary endpoint was overall survival (OS); additional endpoints were progression-free survival, objective response rate, and safety. RESULTS: In patients with prior cetuximab exposure, the median OS was 7.1 months with nivolumab versus 5.1 months with IC (HR, 0.84; 95% CI, 0.62-1.15); OS benefit with nivolumab was maintained across most demographic subgroups. In patients without prior cetuximab exposure, the median OS was 8.2 months with nivolumab versus 4.9 months with IC (HR, 0.52; 95% CI, 0.35-0.77); OS benefit with nivolumab was maintained across patient baseline subgroups including tumor programmed death ligand 1 (PD-L1) expression (<1% or ≥1%). Grade 3-4 treatment-related adverse event rates favored nivolumab versus IC in both subgroups. CONCLUSIONS: Nivolumab appeared to improve efficacy versus IC regardless of prior cetuximab use, supporting its use in patients with R/M SCCHN with or without prior cetuximab exposure. The reduction in risk of death with nivolumab compared with IC was greater in patients without prior cetuximab exposure versus with prior cetuximab exposure.
Citation
Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 25 (17), pp. 5221 - 5230
Source Title
Publisher
AMER ASSOC CANCER RESEARCH
ISSN
1078-0432
eISSN
1557-3265
Research Team
Targeted Therapy